Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency

Journal of Heart and Lung Transplantation

Volumn 34, Issue 7, 2015, Pages 958-962

  Burrows, Fay S ^a,b   Carlos, Lilibeth M ^a,b   Benzimra, Mark ^b   Marriott, Deborah J E ^a   Havryk, Adrian P ^b   Plit, Marshall L ^b   Malouf, Monique A ^b   Glanville, Allan R ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b Lung Transplant Unit   (Australia)

Author keywords

CLAD; Lung transplantation; ribavirin; RSV

Indexed keywords

AZITHROMYCIN; COTRIMOXAZOLE; DAPSONE; GANCICLOVIR; HEMOGLOBIN; PENTAMIDINE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RIBAVIRIN; ROXITHROMYCIN; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BRONCHIOLITIS OBLITERANS; CAUSE OF DEATH; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEMOLYTIC ANEMIA; HOSPITAL PATIENT; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LOADING DRUG DOSE; LUNG FUNCTION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; THROAT CULTURE; TREATMENT DURATION; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931565443     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2015.01.009     Document Type: Article

References (22)

1. S.M. Palmer Jr, N.G. Henshaw, and D.N. Howell Community respiratory viral infection in adult lung transplant recipients Chest 113 1998 944 950
2. T.N. Small, A. Casson, and S.F. Malak Respiratory syncytial virus infection following hematopoietic stem cell transplantation Bone Marrow Transplant 29 2002 321 327
3. L.H. McCurdy, A. Milstone, and S. Dummer Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin J Heart Lung Transplant 22 2003 745 753
4. P. Hopkins, K. McNeil, and F. Kermeen Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus Am J Respir Crit Care Med 178 2008 876 881
5. D. Hayes Jr, H.M. Mansour, and S. Kirkby Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection Transpl Infect Dis 14 2012 548 550
6. L.M. Hynicka, and C.R. Ensor Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients Ann Pharmacother 46 2012 558 566
7. L. Li, R. Avery, and M. Budev Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation J Heart Lung Transplant 31 2012 839 844
8. A.R. Glanville, A.I. Scott, and J.M. Morton Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation J Heart Lung Transplant 24 2005 2114 2119
9. V. Liu, G.S. Dhillon, and D. Weill A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients Transpl Infect Dis 12 2010 38 44
10. M.R. Zamora, M. Budev, and M. Rolfe RNA interference therapy in lung transplant patients infected with respiratory syncytial virus Am J Respir Crit Care Med 183 2011 531 538
11. J.P. DeVincenzo, R.J. Whitley, and R.L. Mackman Oral GS-5806 activity in a respiratory syncytial virus challenge study N Engl J Med 371 2014 711 722
12. M. Estenne, J.R. Maurer, and A. Boehler Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria J Heart Lung Transplant 21 2002 297 310
13. A.R. Glanville, C.L. Aboyoun, J.M. Morton, M. Plit, and M.A. Malouf Cyclosporine C2 target levels and acute cellular rejection after lung transplantation J Heart Lung Transplant 25 2006 928 934
14. A.R. Glanville Chlamydia pneumoniae is associated with graft dysfunction after lung transplantation J Heart Lung Transplant 20 2001 171
15. A.R. Glanville Bronchoscopic monitoring after lung transplantation Semin Respir Crit Care Med 31 2010 208 221
16. A.R. van Zanten, P.M. Engelfriet, and K. van Dillen Importance of nondrug costs of intravenous antibiotic therapy Crit Care 7 2003 R184 R190
17. A.P. Khalifah, R.R. Hachem, and M.M. Chakinala Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death Am J Respir Crit Care Med 170 2004 181 187
18. J. Gottlieb, T.F. Schulz, and T. Welte Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study Transplantation 87 2009 1530 1537
19. T. Fuehner, M. Dierich, and C. Duesberg Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections Antivir Ther 16 2011 733 740
20. A. Pelaez, G.M. Lyon, and S.D. Force Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection J Heart Lung Transplant 28 2009 67 71
21. J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, and V. Soriano Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C J Antimicrob Chemother 62 2008 1174 1180
22. N. Khanna, A.F. Widmer, and M. Decker Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature Clin Infect Dis 46 2008 402 412